SAN RAFAEL, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it will effect a reverse stock split of shares of its common stock at a ratio of 1-for-15, effective as of May 27, 2025 at 12:01 a.m. Pacific time. The Company’s common stock will open for trading on The Nasdaq Capital Market on May 27, 2025 on a split-adjusted basis under the existing symbol “EKSO”. The Comp ...

Core Viewpoint - ASP Isotopes Inc. has entered into multiple agreements with TerraPower to support the construction of a new uranium enrichment facility in South Africa, aimed at producing High Assay Low-Enriched Uranium (HALEU) for various industries [1][4]. Financing and Agreements - The Loan Agreement with TerraPower includes conditional commitments for a term loan to finance the new uranium enrichment facility at Pelindaba, South Africa [2]. - The Company is also seeking additional capital from financial institutions, which is expected to be non-dilutive to shareholders [2]. Facility Details - The initial HALEU production facility will be located at Pelindaba, South Africa, pending necessary permits and licenses [3]. - The facility is designed to produce approximately 15 metric tons of HALEU annually, with initial production expected to start in 2027 [4]. Job Creation and Economic Impact - The construction of the facility is anticipated to create hundreds of full-time jobs and support thousands of additional jobs across a manufacturing supply chain [4][8]. Supply Agreements - Two supply agreements have been established with TerraPower for HALEU, including a core supply agreement for the Natrium project in Wyoming and a long-term agreement for up to 150 metric tons of HALEU from 2028 to 2037 [5][7]. Technology and Innovation - The Company utilizes two proprietary enrichment technologies: the Aerodynamic Separation Process and the Quantum Enrichment Process, which are expected to lower capital costs and reduce construction time compared to traditional methods [6][9]. - There is a growing demand for various isotopes, including those for healthcare and green energy applications, which the Company aims to address through its advanced technologies [9].

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Aether Holdings, Inc. (Nasdaq: ATHR) (“Aether” or the “Company”), an emerging financial technology platform company that offers proprietary research analytics, today announced that its management team is scheduled to present at the Aegis Capital Corp. 2025 Virtual Conference on Thursday, May 22nd, 2025. Presentation Details:Date: May 22nd, 2025Time: 2:00 p.m. ETWebcast Registration: https://us02web.zoom.us/meeting/register/AfmnLxICTqmjEvoSG9-MMQ Frank Cid, VP of Bu ...

NASHVILLE, Tenn., May 19, 2025 (GLOBE NEWSWIRE) -- Ryman Hospitality Properties, Inc. (NYSE: RHP) (the “Company”) today announced that it has commenced an underwritten registered public offering (the “Offering”) of 2,300,000 shares of its common stock, par value $0.01 per share. The Company expects to grant the underwriters a 30-day option to purchase up to 345,000 additional shares of common stock. The Company expects to contribute the net proceeds of the Offering to RHP Hotel Properties, LP (the “Operatin ...

Core Points - Reading International, Inc. is scheduled to participate in Sidoti's Virtual Micro-Cap Investor Conference on May 21-22, 2025 [1] - The company's Executive Vice President – Global Operations, Andrzej Matyczynski, will present virtually on May 22, 2025, at 10:45 A.M. Eastern time, discussing financial results, business outlook, and capital allocation strategy [2] - The investor presentation will be available on the company's corporate website after the conference [3] Company Overview - Reading International, Inc. is an internationally diversified cinema and real estate company with operations in the United States, Australia, and New Zealand [4] - The company operates various cinema brands, including Reading Cinemas, Consolidated Theatres, and Angelika, and owns live theatres under the Liberty Theaters subsidiary [5] - Signature property developments include Newmarket Village in Brisbane, Australia, and 44 Union Square in New York City [5]

PHOENIX, May 19, 2025 (GLOBE NEWSWIRE) -- Leslie’s, Inc. (NASDAQ: LESL), the largest and most trusted direct-to-customer brand in the U.S. pool and spa care industry serving residential customers and pool professionals nationwide, recently launched its refreshed Pool Perks Rewards Program with the introduction of loyalty tiers. This program is making a splash as pool owners dive into summer focused on ensuring their backyard oasis is clean, safe and beautiful for another season of making memories. “Everythi ...

Core Viewpoint - Zymeworks Inc. is advancing its clinical-stage pipeline with the presentation of new preclinical data for ZW1528, a bispecific molecule targeting IL-4Rα and IL-33, aimed at treating respiratory inflammation, particularly chronic obstructive pulmonary disease (COPD) [1][2]. Group 1: Product Development - ZW1528 demonstrates high affinity binding to IL-4Rα and IL-33, effectively blocking IL-4, IL-13, and IL-33 signaling pathways, which are critical in respiratory inflammation [5][6]. - The bispecific design of ZW1528 shows promising manufacturability and stability, supporting high dosing concentrations and subcutaneous administration [5][7]. - Zymeworks is also developing ZW1572, another bispecific inhibitor targeting IL-4Rα and IL-31 for atopic dermatitis, as part of its expanding IL-4Rα program portfolio [3][5]. Group 2: Preclinical Data and Findings - Preclinical data presented at the ATS conference indicate that ZW1528 can suppress both Type 2 and non-Type 2 immune responses in primary human immune cells from COPD patients [6][7]. - In vivo studies in murine models of lung inflammation show efficacy for ZW1528, with extended pharmacokinetics observed in rodent and non-human primate models [6][7]. - The bispecific antibody's blockade of cytokine-driven activation in human epithelial cells is superior to that achieved with monoclonal antibodies targeting either IL-4Rα or IL-33 [7]. Group 3: Company Overview - Zymeworks is a global biotechnology company focused on developing multifunctional biotherapeutics for difficult-to-treat conditions, including cancer and autoimmune diseases [8]. - The company has a robust pipeline of product candidates and has entered into strategic partnerships to enhance its therapeutic platforms [8].

Core Viewpoint - Opendoor Technologies Inc. has successfully completed a transaction involving the exchange of its 2026 Convertible Senior Notes for new 2030 Convertible Senior Notes, raising $325 million in total, which includes $75.3 million in cash to strengthen its balance sheet and support its mission in the residential real estate market [1][2]. Group 1: Transaction Details - The company issued $325 million in 2030 Convertible Senior Notes, which includes approximately $245.8 million exchanged for 2026 Notes and $79.2 million raised in cash [1]. - The 2030 Notes have a 7.000% annual interest rate and will mature on May 15, 2030, unless converted or repurchased earlier [2][3]. - The gross proceeds from the cash subscription are expected to be around $75.3 million, intended for general corporate purposes [2]. Group 2: Conversion and Redemption Features - The initial conversion rate for the 2030 Notes is set at 637.1050 shares of common stock per $1,000 principal amount, equating to an initial conversion price of approximately $1.57 per share, representing an 80% premium over the last reported share price of $0.872 [4]. - Holders of the 2030 Notes can require the company to repurchase their notes at 100% of the principal amount upon a fundamental change [5]. - The company can redeem the 2030 Notes starting May 22, 2028, if the stock price exceeds 130% of the conversion price for a specified period [5]. Group 3: Advisory and Additional Information - J. Wood Capital Advisors LLC acted as the advisor for the transaction [6]. - For further details regarding the transaction, the company has filed a Current Report on Form 8-K with the SEC [6].

Core Insights - CRISPR Therapeutics and Sirius Therapeutics have formed a strategic partnership to co-develop and commercialize SRSD107, a long-acting Factor XI (FXI) small interfering RNA (siRNA) for thromboembolic disorders [1][2] - SRSD107 has shown promising results in Phase 1 clinical trials, achieving over 93% reduction in FXI activity and more than twofold increase in activated partial thromboplastin time (aPTT), with effects lasting up to 6 months post-dosing [1][3] - The collaboration includes an upfront payment of $25 million in cash and $70 million in equity from CRISPR to Sirius, with a 50-50 cost and profit-sharing structure for SRSD107 [1][8] Company Overview - CRISPR Therapeutics is focused on creating transformative gene-based medicines and has a diverse portfolio across various disease areas, including cardiovascular diseases [10] - Sirius Therapeutics is a clinical-stage biotech company developing innovative siRNA therapies, with SRSD107 being its most advanced product targeting thromboembolic disorders [17][18] Clinical Development - The clinical program for SRSD107 includes two Phase 1 trials demonstrating safety and robust pharmacodynamic effects, with a Phase 2 trial planned to evaluate its efficacy in preventing venous thromboembolism (VTE) in total knee arthroplasty patients [3][7] - SRSD107 is designed to selectively inhibit FXI, aiming to reduce thrombotic events while minimizing bleeding risks, offering a differentiated approach compared to existing therapies [2][16] Market Potential - Thromboembolic disorders are a significant global health issue, affecting millions and representing a substantial unmet medical need [2][15] - The addressable patient population for SRSD107 includes those with atrial fibrillation, venous thromboembolism, cancer-associated thrombosis, and other conditions where existing therapies pose bleeding risks [2][3]

Core Insights - BitMine Immersion Technologies, Inc. has launched a Bitcoin Treasury Advisory Practice and completed a $4 million strategic transaction with a U.S. exchange-listed company [1][2] - The company is offering "Mining as a Service" (MaaS) to its strategic partner and plans to extend this service to other companies holding Bitcoin [1][3] - The strategic agreement includes leasing 3,000 Bitcoin ASIC miners for $3.2 million, with $1.6 million paid upfront, and an additional $800,000 consulting agreement for one year [2][3] Company Overview - BitMine focuses on Bitcoin mining, Synthetic Bitcoin Mining, and providing advisory services to companies interested in Bitcoin-denominated revenues [5] - The company operates in low-cost energy regions, including Trinidad and Texas [5] Market Context - Nearly 100 public companies have adopted Bitcoin as a treasury holding, with expectations for this number to grow [4] - The CEO of BitMine highlighted that the current transaction exceeds the company's entire revenue for the 2024 fiscal year, indicating strong growth potential in the Bitcoin advisory market [4]